{
    "clinical_study": {
        "@rank": "63677", 
        "arm_group": [
            {
                "arm_group_label": "Part 1: Faldaprevir + Itraconazole", 
                "arm_group_type": "Experimental", 
                "description": "Interaction of Faldaprevir and Itraconazole"
            }, 
            {
                "arm_group_label": "Part 2:Faldaprevir+Rosuvastatin+Atorvast", 
                "arm_group_type": "Experimental", 
                "description": "Interaction of Faldaprevir, Rosuvastatin and Atorvastatin"
            }
        ], 
        "brief_summary": {
            "textblock": "To investigate the effect of steady-state itraconazole on the pharmacokinetics of\n      steady-state of faldaprevir and the effect of steady-state of faldaprevir on the single-dose\n      pharmacokinetics of atorvastatin as well as the effect of steady-state of faldaprevir on the\n      single-dose pharmacokinetics of rosuvastatin"
        }, 
        "brief_title": "Investigation of Interactions Between Faldaprevir, Itraconazole, Atorvastatin and Rosuvastatin", 
        "completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n        1. Healthy male and female subjects\n\n        Exclusion criteria:\n\n        1. Any relevant deviation from healthy conditions"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "51", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01795937", 
            "org_study_id": "1220.61", 
            "secondary_id": "2012-005518-20"
        }, 
        "intervention": [
            {
                "arm_group_label": "Part 1: Faldaprevir + Itraconazole", 
                "description": "twice daily", 
                "intervention_name": "Itraconazole", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Part 2:Faldaprevir+Rosuvastatin+Atorvast", 
                "description": "single dose", 
                "intervention_name": "Atorvastatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Part 2:Faldaprevir+Rosuvastatin+Atorvast", 
                "description": "once daily", 
                "intervention_name": "Faldaprevir", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Part 2:Faldaprevir+Rosuvastatin+Atorvast", 
                "description": "single dose", 
                "intervention_name": "Rosuvastatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Part 1: Faldaprevir + Itraconazole", 
                "description": "once daily", 
                "intervention_name": "Faldaprevir", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Itraconazole", 
                "Hydroxyitraconazole", 
                "Atorvastatin", 
                "Rosuvastatin"
            ]
        }, 
        "lastchanged_date": "July 10, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Ingelheim", 
                    "country": "Germany"
                }, 
                "name": "1220.61.1 Boehringer Ingelheim Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "Investigation of Interactions Between Faldaprevir, Itraconazole, Atorvastatin and Rosuvastatin in Healthy Male and Female Subjects (Open-label, Fixed-sequence)", 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "AUCt,ss  (area under the concentration-time curve of the analyte in plasma at steady state over the dosing interval) for faldaprevir", 
                "safety_issue": "No", 
                "time_frame": "up to 6 days"
            }, 
            {
                "measure": "Cmax,ss (maximum measured concentration of the analyte in plasma at steady state over the dosing interval) for faldaprevir", 
                "safety_issue": "No", 
                "time_frame": "up to 6 days"
            }, 
            {
                "measure": "AUC0-infinity (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity after single dose administration) for atorvastatin or rosuvastatin", 
                "safety_issue": "No", 
                "time_frame": "up to 3 days"
            }, 
            {
                "measure": "Cmax (maximum measured concentration of the analyte in plasma) for atorvastatin and rosuvastatin", 
                "safety_issue": "No", 
                "time_frame": "up to 3 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01795937"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "AUCt,ss (area under the concentration-time curve of the analyte in plasma at steady state over the dosing interval t) for faldaprevir", 
                "safety_issue": "No", 
                "time_frame": "up to 3 days"
            }, 
            {
                "measure": "Cmax,ss (maximum measured concentration of the analyte in plasma at steady state over the dosing interval) for faldaprevir", 
                "safety_issue": "No", 
                "time_frame": "up to 3 days"
            }, 
            {
                "measure": "AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point) for atorvastatin or rosuvastatin", 
                "safety_issue": "No", 
                "time_frame": "up to 3 days"
            }
        ], 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}